|
||
| |||||||
|
Cobra extends its agreement with Oncolytics Biotech Inc. to provide long term manufacture of REOLYSIN® Keele, UK, 8 February 2005
– Cobra Biomanufacturing Plc (London Stock Exchange AIM: CBF.L), the
international manufacturer of biopharmaceuticals, announces today that it has
extended its agreement with Oncolytics Biotech Inc. (NASDAQ: ONCY, TSX: ONC) to
provide additional cGMP production and clinical trial supply material of
REOLYSIN®. This anticancer product is a proprietary formulation
based on the Reovirus and has showed promising results in Phase I clinical
trials. The value of the agreement is in excess of £750,000 for 2005.
David Thatcher, CEO of Cobra said: “I am delighted that we have been successfully re-appointed by Oncolytics Biotech Inc. and we very much look forward to continuing our relationship. This agreement further endorses our ability to both manufacture challenging viral products, as well as build a North American customer base. We wish Oncolytics every success in their next clinical trials and will do all we can by supplying high quality product to meet their timelines.”
Brad Thompson, President and CEO of Oncolytics Biotech commented: “Advancing and expanding our human clinical trials in 2005 is driving our need for further supply. We are pleased with the work done for us by Cobra to date, and so going back to them for further, extended supply was an obvious decision.”
-Ends-
About Cobra Biomanufacturing Plc Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the life science industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe. A range of unique, patented technologies, underpins this revenue generating business.
Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK
|
|
| ||||||||
